Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 19/20 | 0.61 |
| ▸ | KCNQ2 | O43526 | 19/20 | 0.61 |
| ▸ | KCNE1 | P15382 | 14/20 | 0.61 |
| ▸ | KCNQ1 | P51787 | 14/20 | 0.61 |
| ▸ | BACE1 | P56817 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21623567 | 0.82 | CYP1A2 (0.60) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL5214671 | 0.81 | KCNQ3 (0.78) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL21623225 | 0.78 | CA2 (0.57) | KCNQ3KCNQ2KCNE1KCNQ1CA1 | |
| SCHEMBL21623273 | 0.78 | KCNQ3 (0.73) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL5213999 | 0.77 | KCNQ3 (0.77) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL5215207 | 0.77 | KCNQ3 (0.81) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL5214441 | 0.76 | KCNQ3 (1.00) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL21623152 | 0.76 | LMNA (0.55) | KCNQ3KCNQ2KCNE1KCNQ1CA1 | |
| SCHEMBL5213995 | 0.74 | KCNQ3 (0.77) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL21623376 | 0.74 | CYP1A2 (0.65) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210276967-A1 | INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2021-09-09 | — | — | US | disclosed |
| US-20210276967-A1 | INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2021-09-09 | — | — | US | disclosed |
| CN-112912368-A | Inhibitors of hepatitis B virus | 圣拉斐尔医院有限公司 | 2021-06-04 | — | — | CN | disclosed |
| EP-3823957-A1 | INHIBITORS OF HEPATITIS B VIRUS | Ospedale San Raffaele S.r.l. (IT) | 2021-05-26 | — | — | EP | disclosed |
| WO-2020016427-A1 | INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2020-01-23 | — | — | WO | disclosed |
| WO-2020016427-A1 | INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2020-01-23 | — | — | WO | disclosed |
| WO-2020016434-A1 | CYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2020-01-23 | — | — | WO | disclosed |
| WO-2020016434-A1 | CYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2020-01-23 | — | — | WO | disclosed |
| EP-3597637-A1 | INHIBITORS OF HEPATITIS B VIRUS | IRBM S.P.A. (IT) | 2020-01-22 | — | — | EP | disclosed |
| EP-3597653-A1 | CYCLIC INHIBITORS OF HEPATITIS B VIRUS | IRBM S.P.A. (IT) | 2020-01-22 | — | — | EP | disclosed |
| EP-3597637-A1 | INHIBITORS OF HEPATITIS B VIRUS | IRBM S.P.A. (IT) | 2020-01-22 | — | — | EP | disclosed |
| EP-3597653-A1 | CYCLIC INHIBITORS OF HEPATITIS B VIRUS | IRBM S.P.A. (IT) | 2020-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210276967-A1 | INHIBITORS OF HEPATITIS B VIRUS | HAVCR2, SLC10A1, HDGF | KCNQ3 4616/4885KCNQ2 4490/4885KCNE1 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.